Supplemental Table II.
Clinical demographics and treatment outcomes
| No. | Age (yr) | Sex | Ethnicity | Medical history | Treatment regimen | Treatment outcome |
|---|---|---|---|---|---|---|
| 1 | 54 | Female | Hispanic | Hypothyroidism | Triamcinolone 0.1% cream 3-wk prednisone taper (60 mg: 40:20) 5-mo isotretinoin taper (40 mg: 20:20:20:10) |
Complete resolution but with mild relapse after 16 mo |
| 2 | 47 | Female | Hispanic | None | Halobetasol 0.05% ointment 3-wk prednisone taper (60 mg: 40:20) 4-mo isotretinoin taper (40 mg: 20:20:10) |
Marked clinical improvement without recurrence at 24 mo |
| 3 | 54 | Female | Hispanic | Sjogren syndrome, fibromyalgia | Halobetasol 0.05% ointment 3-wk prednisone taper (60 mg: 40:20) 3-mo isotretinoin taper (20 mg: 20:10) |
Marked clinical improvement but with subjective recurrence at 2 mo |
| 4 | 54 | Female | Hispanic | DM II, HTN | Halobetasol 0.05% ointment 3-wk prednisone taper (60 mg: 40:20) 1-mo isotretinoin, 20 mg/d |
Complete resolution without recurrence at 2 mo |
DM, Diabetes mellitus; HTN, hypertension.